Peter,
But don't you assume, that 1)if Ponatinib is demonstrated to be clearly superior in a head to head trial(becoming 1st line),
and 2)that it's greatest efficacy long-term continues to result from earliest initiation,
that most(if not all) insurances will be forced to reimburse for it, regardless of cost pressures?
If 1&2, would Gleevec and others all then be relegated to 2nd line?
Thanks, and
Regards,
bw